Table 4.
Prospective Ongoing Study on Neoadjuvant Chemotherapy for Pancreatic Cancer before Radical Resection
| Author/trial | Phase | Start year | Resectability | Treatment | Scheduled number of patients | Primary outcome |
|---|---|---|---|---|---|---|
| Labori et al. NorPACT-173 | II/III | 2017 | R | mFOLFIRINOX → surgery → GEM + capecitabine | 140 | OS |
| Surgery → GEM + capecitabine | ||||||
| Schwarz et al. PANACHE01-PRODIGE4874 | II | 2017 | R | mFOLFIRINOX → surgery → adjuvant therapy | 160 | OS |
| FOLFOX → surgery → adjuvant therapy | ||||||
| Surgery → adjuvant therapy | ||||||
| Ferrone Alliance A02180675 | III | 2020 | R | mFOLFIRINOX → surgery →mFOLFIRINOX | 352 | OS |
| Surgery →mFOLFIRINOX | ||||||
| Koerkamp PREOPANC-376 | III | 2021 | R | mFOLFIRINOX → surgery →mFOLFIRINOX | 378 | OS |
| Surgery → mFOLFIRINOX | ||||||
| Janssen et al. PREOPANC-277 | III | 2018 | R/BR | mFOLFIRINOX → surgery | 368 | OS |
| GEM → CRT (36 Gy, GEM) → GEM → surgery → GEM | ||||||
| Grose et al. PRIMUS-00278 | II | 2019 | R/BR | FOLFOX + nab-PTX → CRT → surgery | 278 | PFS |
| GEM + nab-PTX → CRT → surgery | ||||||
| Unno Prep-03/NS014-179 | I/II | 2014 | BR | GEM + S-1 + concurrent RT (50 Gy) → surgery | 12–24/40 | R0 |
| Okada et al. NAC-GA80 | II | 2017 | BR | GEM + nab-PTX → surgery | 60 | OS |
| Takahashi GABARNANCE81 | II/III | 2017 | BR | GEM + nab-PTX → surgery | 110 | R0/OS |
| CRT (54 Gy, S-1) → surgery |
R, resectable; mFOLFIRINOX, modified FOLFIRINOX; GEM, gemcitabine; OS, overall survival; BR, borderline resectable; CRT, chemoradiotherapy; nab-PTX, nab-paclitaxel; RT, radiotherapy; PFS, progression-free survival.